BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33836183)

  • 1. Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients.
    Minoia F; Tibaldi J; Muratore V; Gallizzi R; Bracaglia C; Arduini A; Comak E; Vougiouka O; Trauzeddel R; Filocamo G; Mastrangelo A; Micalizzi C; Kasapcopur O; Unsal E; Kitoh T; Tsitsami E; Kostik M; Schmid JP; Prader S; Laube G; Maritsi D; Jelusic M; Shenoi S; Vastert S; Ardissino G; Cron RQ; Ravelli A;
    J Pediatr; 2021 Aug; 235():196-202. PubMed ID: 33836183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
    Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
    Naveen R; Jain A; Muhammed H; Gupta L; Misra DP; Lawrence A; Agarwal V; Misra R; Aggarwal A
    Rheumatol Int; 2021 Mar; 41(3):625-631. PubMed ID: 33388903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
    Huang S; Liu Y; Yan W; Zhang T; Wang P; Zhu M; Zhang X; Zhou P; Fan Z; Yu H
    Pediatr Rheumatol Online J; 2024 May; 22(1):58. PubMed ID: 38783316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
    Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
    World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
    Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
    J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Minoia F; Bovis F; Davì S; Horne A; Fischbach M; Frosch M; Huber A; Jelusic M; Sawhney S; McCurdy DK; Silva CA; Rigante D; Unsal E; Ruperto N; Martini A; Cron RQ; Ravelli A;
    Ann Rheum Dis; 2019 Oct; 78(10):1357-1362. PubMed ID: 31296501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.
    Gloude NJ; Dandoy CE; Davies SM; Myers KC; Jordan MB; Marsh RA; Kumar A; Bleesing J; Teusink-Cross A; Jodele S
    J Clin Immunol; 2020 Jul; 40(5):699-707. PubMed ID: 32447592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
    Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
    Minoia F; Davì S; Horne A; Demirkaya E; Bovis F; Li C; Lehmberg K; Weitzman S; Insalaco A; Wouters C; Shenoi S; Espada G; Ozen S; Anton J; Khubchandani R; Russo R; Pal P; Kasapcopur O; Miettunen P; Maritsi D; Merino R; Shakoory B; Alessio M; Chasnyk V; Sanner H; Gao YJ; Huasong Z; Kitoh T; Avcin T; Fischbach M; Frosch M; Grom A; Huber A; Jelusic M; Sawhney S; Uziel Y; Ruperto N; Martini A; Cron RQ; Ravelli A; ; ; ;
    Arthritis Rheumatol; 2014 Nov; 66(11):3160-9. PubMed ID: 25077692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.
    Lin CI; Yu HH; Lee JH; Wang LC; Lin YT; Yang YH; Chiang BL
    Clin Rheumatol; 2012 Aug; 31(8):1223-30. PubMed ID: 22615046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
    de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
    Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis.
    Çakan M; Karadağ ŞG; Tanatar A; Ayaz NA
    Mod Rheumatol; 2020 Sep; 30(5):900-904. PubMed ID: 31462146
    [No Abstract]   [Full Text] [Related]  

  • 17. Refractory secondary thrombotic microangiopathy with kidney injury associated with systemic lupus erythematosus in a pediatric patient.
    Kaneda T; Tanaka E; Akutsu Y; Kanamori T; Mouri M; Morio T; Mori M
    CEN Case Rep; 2020 Nov; 9(4):301-307. PubMed ID: 32304042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
    Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
    Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developed during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report.
    Mouri M; Kanamori T; Tanaka E; Hiratoko K; Okubo M; Inoue M; Morio T; Shimizu M; Nishino I; Okiyama N; Mori M
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):404-409. PubMed ID: 36416547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Likhacheva TS; Isupova EA; Glebova NI; Kuchinskaya EM; Balbotkina EV; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Semin Arthritis Rheum; 2015 Feb; 44(4):417-22. PubMed ID: 25300700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.